<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="epub">2692-8205</issn></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS207359</article-id><article-id pub-id-type="doi">10.1101/2025.07.14.664731</article-id><article-id pub-id-type="archive">PPR1052113</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">1</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Differential chromatin response to retinoic acid in neuroblastoma according to type of <italic>ATRX</italic> mutation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lorenzi</surname><given-names>Federica</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Shipley</surname><given-names>Matthew</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Deane</surname><given-names>Luke</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Goldstone</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Tandon</surname><given-names>Vidur</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>da Costa</surname><given-names>Barbara Martins</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Greenslade</surname><given-names>Kevin</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Barker</surname><given-names>Karen</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Nemati</surname><given-names>Fariba</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Bellini</surname><given-names>Angela</given-names></name><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Schleiermacher</surname><given-names>Gudrun</given-names></name><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Chesler</surname><given-names>Louis</given-names></name><xref ref-type="aff" rid="A4">4</xref><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Guillemot</surname><given-names>Francois</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>George</surname><given-names>Sally L</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A7">7</xref></contrib></contrib-group><aff id="A1"><label>1</label>Developmental Oncology Group, Division of Clinical Studies, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/043jzw605</institution-id><institution>The Institute of Cancer Research</institution></institution-wrap>, <city>London</city>, <postal-code>SM2 5AG</postal-code>, <country country="GB">United Kingdom</country></aff><aff id="A2"><label>2</label>Neural Stem Cell Biology Laboratory, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/04tnbqb63</institution-id><institution>The Francis Crick Institute</institution></institution-wrap>, <city>London</city>, <postal-code>NW1 1AT</postal-code>, <country country="GB">United Kingdom</country></aff><aff id="A3"><label>3</label>Bioinformatics and Biostatistics Science and Technology Platform, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/04tnbqb63</institution-id><institution>The Francis Crick Institute</institution></institution-wrap>, <city>London</city><postal-code>NW1 1AT</postal-code>, <country country="GB">United Kingdom</country></aff><aff id="A4"><label>4</label>Paediatric Solid Tumour Biology and Therapeutics Group, Division of Clinical Studies, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/043jzw605</institution-id><institution>The Institute of Cancer Research</institution></institution-wrap>, <city>London</city>, <postal-code>SM2 5AG</postal-code>, <country country="GB">United Kingdom</country></aff><aff id="A5"><label>5</label>Laboratory of Preclinical Investigation, Department of Translational Research, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/04t0gwh46</institution-id><institution>Institut Curie</institution></institution-wrap>, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/013cjyk83</institution-id><institution>PSL University Paris</institution></institution-wrap>, <postal-code>75005</postal-code><city>Paris</city>, <country country="FR">France</country></aff><aff id="A6"><label>6</label>SiRIC RTOP (Recherche Translationelle en Oncologie Pediatrique), U1330 <institution-wrap><institution-id institution-id-type="ror">https://ror.org/02vjkv261</institution-id><institution>INSERM</institution></institution-wrap> and SIREDO Integrated Pediatric Oncology Center, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/04t0gwh46</institution-id><institution>Institut Curie</institution></institution-wrap>, <addr-line>26 Rue d’Ulm</addr-line>, <postal-code>75005</postal-code><city>Paris</city>, <country country="FR">France</country></aff><aff id="A7"><label>7</label>Children and Young People’s Unit, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/034vb5t35</institution-id><institution>The Royal Marsden Hospital</institution></institution-wrap>, <city>London</city>, <postal-code>SM2 5PT</postal-code>, <country country="GB">United Kingdom</country></aff><author-notes><corresp id="CR1">Corresponding author: Dr Sally L George, <email>sally.george@icr.ac.uk</email>
</corresp></author-notes><pub-date pub-type="nihms-submitted"><day>22</day><month>07</month><year>2025</year></pub-date><pub-date pub-type="preprint"><day>18</day><month>07</month><year>2025</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p></license></permissions><abstract><p id="P1">Neuroblastoma is a childhood cancer, arising in the developing sympathetic nervous system. Differentiation therapy with 13-cis-retinoic acid (RA) is routinely given to children with high-risk neuroblastoma in the minimal residual disease setting to prevent relapse, however there is little understanding of which patients benefit from RA therapy.</p><p id="P2"><italic>ATRX</italic> alterations are identified in 10% of high-risk neuroblastomas and associated with poor outcomes. The commonest type of <italic>ATRX</italic> alterations in neuroblastoma are in-frame multi-exon deletions, followed by nonsense mutations predicted to result in loss-of-function (<italic>ATRX</italic> LoF).</p><p id="P3">We treated paired <italic>ATRX</italic> wild-type and <italic>ATRX</italic> LoF neuroblastoma cell lines with RA and show that cells with <italic>ATRX</italic> LoF fail to upregulate direct RA target genes. Cells with <italic>ATRX</italic> LoF also show reduced chromatin accessibility at genes involved in differentiation and development following RA treatment. Conversely, neuroblastoma models with in-frame deletions mount a response to RA and show <italic>in-vitro</italic> sensitivity to RA. Taken together this shows that the mechanism of differentiation in <italic>ATRX</italic>-altered neuroblastoma depends on the type of <italic>ATRX</italic> alteration, with implications relating to both oncogenesis and therapeutic response.</p></abstract><kwd-group><kwd>ATAC</kwd><kwd>ATRX</kwd><kwd>Neuroblastoma</kwd><kwd>Retinoic acid</kwd></kwd-group></article-meta></front><body><sec id="S1" sec-type="intro"><title>Introduction</title><p id="P4">Neuroblastoma is a heterogenous cancer of the sympathetic nervous system, arising in cells of neural crest lineage during embryonal development. It can spontaneously differentiate and regress, however more frequently it presents in young children as an aggressive, widely metastatic malignancy. A limited number of genetic alterations have been identified as drivers of neuroblastoma, including somatic <italic>ATRX</italic> gene alterations which are identified in 10% of high-risk neuroblastomas and define a distinct sub-group of patients with chronic, slowly progressive disease [<xref ref-type="bibr" rid="R1">1</xref>–<xref ref-type="bibr" rid="R3">3</xref>].</p><p id="P5"><italic>ATRX</italic> codes for a chromatin remodeling protein with far reaching functions. It has multiple roles including the maintenance of genomic stability at repetitive DNA regions and the resolution of R-loops, G quadruplexes and stalled replication forks. ATRX is also known to regulate cell-state specific gene expression via multiple different mechanisms [<xref ref-type="bibr" rid="R4">4</xref>].</p><p id="P6">The most frequent type of <italic>ATRX</italic> alterations seen in neuroblastoma are in-frame multi-exon deletions, most commonly resulting in the loss of exons 2-10 of the gene (containing the EZH2 and ADD domains), and resulting in an in-frame fusion (IFF) protein [<xref ref-type="bibr" rid="R5">5</xref>, <xref ref-type="bibr" rid="R6">6</xref>]. The remainder of <italic>ATRX</italic> alterations are either nonsense mutations predicted to result in loss of function (LoF) (18%), and missense mutations, which tend to cluster in the helicase domain of the gene (14%) [<xref ref-type="bibr" rid="R7">7</xref>, <xref ref-type="bibr" rid="R8">8</xref>]. These different types of alterations are all universally associated with certain biological characteristics such as the presence of alternative lengthening of telomeres [<xref ref-type="bibr" rid="R5">5</xref>] and an immunogenic phenotype [<xref ref-type="bibr" rid="R9">9</xref>]. However, evidence is mounting that there are also significant differences between <italic>ATRX</italic> IFF and <italic>ATRX</italic> LoF neuroblastoma in the underlying mechanisms of epigenetic deregulation [<xref ref-type="bibr" rid="R6">6</xref>, <xref ref-type="bibr" rid="R7">7</xref>]. In <italic>ATRX</italic> IFF neuroblastoma it has been shown that differentiation block is mediated by a non-canonical function of the <italic>ATRX</italic> IFF, activating REST and resulting in repression of neurogenesis genes [<xref ref-type="bibr" rid="R6">6</xref>]. However, how <italic>ATRX</italic> LoF affects neuroblastoma differentiation potential is unknown.</p><p id="P7">Here, we show impairment of the response to differentiation stimuli in both stem cell and neuroblastoma models with ATRX LoF. Neuroblastoma cells with ATRX LoF also show decreased chromatin accessibility at neuronal differentiation genes following treatment with 13-<italic>cis</italic>-retinoic acid (RA) - an agent used as standard-of-care in the minimal residual disease setting to prevent neuroblastoma relapse. Conversely, <italic>ATRX</italic> IFF neuroblastoma models are broadly sensitive to RA and show appropriate opening of chromatin at RA response sites. Taken together this work shows that the mechanism of differentiation block in neuroblastoma depends on the type of <italic>ATRX</italic> alteration, with implications relating to both oncogenesis and therapeutic response.</p></sec><sec id="S2" sec-type="results"><title>Results</title><sec id="S3"><title><italic>ATRX</italic> LoF neuroblastoma cells have an impaired chromatin response to RA compared to their wild-type counterparts</title><p id="P8">To investigate the role of <italic>ATRX</italic> in differentiation, we used paired <italic>ATRX</italic> wild-type (<italic>ATRX</italic> WT) and LoF induced pluripotent stem cells (iPSCs) [<xref ref-type="bibr" rid="R10">10</xref>] to generate human axial progenitor (HAP) cells, as the first step in differentiation towards neural crest lineage (<xref ref-type="supplementary-material" rid="SD1">Fig S1A-E</xref>) [<xref ref-type="bibr" rid="R11">11</xref>]. Upon HAP differentiation, we saw a robust induction of expression of the axial progenitor marker <italic>CDX2</italic> in both <italic>ATRX</italic> WT and LoF iPSCs (<xref ref-type="supplementary-material" rid="SD1">Fig S1F</xref>), however this was only associated with induction of <italic>HOXC</italic> gene expression in <italic>ATRX</italic> WT cells (<xref ref-type="supplementary-material" rid="SD1">Fig S1G</xref>).</p><p id="P9">In normal embryonic development, CDX2 co-ordinates the spatial and temporal expression of <italic>HOX</italic> genes together with RA [<xref ref-type="bibr" rid="R12">12</xref>, <xref ref-type="bibr" rid="R13">13</xref>]. Given that RA is also used clinically as a differentiation therapy for patients with neuroblastoma, we next asked if a similar phenotype was seen when <italic>ATRX</italic> LoF neuroblastoma cells were treated with RA. Paired <italic>ATRX</italic> WT (p53(2)) and <italic>ATRX</italic> LoF (E6) neuroblastoma cells [<xref ref-type="bibr" rid="R14">14</xref>] were treated with RA and evaluated for expression of known RA target genes: <italic>CYP26A, HOXA1</italic> and <italic>HOXA4</italic> [<xref ref-type="bibr" rid="R15">15</xref>]. Concordant with our findings in <italic>ATRX</italic> LoF iPSCs, we also identified a failure of upregulation of direct RA target genes in neuroblastoma cells with <italic>ATRX</italic> LoF (<xref ref-type="fig" rid="F1">Fig 1A-B</xref>).</p><p id="P10">We next analysed sensitivity to RA in the paired cell lines by clonogenic assay. We saw no difference in sensitivity to RA between <italic>ATRX</italic> WT and LoF cells (<xref ref-type="fig" rid="F1">Fig 1C</xref>) however, the parental cell line was already highly retinoic acid resistant. Of note, the parental cell line is derived from a SH-EP cell [<xref ref-type="bibr" rid="R14">14</xref>] which is known to be a mesenchymal cell line with a super-enhancer landscape that associated with RA resistance [<xref ref-type="bibr" rid="R16">16</xref>]. Therefore, we decided to evaluate the direct effects of ATRX LoF on chromatin accessibility by ATAC sequencing (<xref ref-type="fig" rid="F1">Fig 1D-J</xref>).</p><p id="P11">We identified widespread differences in chromatin accessibility in <italic>ATRX</italic> LoF compared with <italic>ATRX</italic> WT neuroblastoma in both vehicle control conditions (<xref ref-type="fig" rid="F1">Fig 1D</xref>, <xref ref-type="supplementary-material" rid="SD1">Table S1</xref>) and upon treatment with RA (<xref ref-type="fig" rid="F1">Fig 1E</xref>, <xref ref-type="supplementary-material" rid="SD1">Table S1</xref>). Transcription factor binding motif analysis of differentially accessible peaks in response to RA also identified that a greater number of both over and under-represented peaks were seen in response to RA in <italic>ATRX</italic> WT cells compared with <italic>ATRX</italic> LoF cells (<xref ref-type="fig" rid="F1">Fig 1F</xref>, <xref ref-type="supplementary-material" rid="SD1">Table S1</xref>).</p><p id="P12">We performed gene ontology (GO) analysis of differential accessibility in gene promoter regions between ATRX LoF and WT cells. Given the large number of terms identified, we used REVIGO [<xref ref-type="bibr" rid="R17">17</xref>] to summarize and remove redundant GO terms (<xref ref-type="fig" rid="F1">Fig 1G-H</xref>). The key GO terms with an increase in accessibility in ATRX LoF cells were in acute inflammatory response pathways (<xref ref-type="fig" rid="F1">Fig 1G-H</xref>), consistent with our work identifying an immunogenic phenotype in <italic>ATRX</italic>-altered neuroblastoma [<xref ref-type="bibr" rid="R9">9</xref>]. Many GO terms with decreased accessibility in <italic>ATRX</italic> LoF cells were identified, both in vehicle control and RA treated conditions, relating to multiple cellular processes (<bold>Fig G-H</bold>). We also evaluated for differences in individual GO terms related to differentiation between <italic>ATRX</italic> LoF and WT cells which identified decreased accessibility in multiple critical pathways in embryonic development in <italic>ATRX</italic> LoF cells compared with WT cells in both vehicle control and RA treated conditions (<xref ref-type="fig" rid="F1">Fig 1I-J</xref>, <xref ref-type="supplementary-material" rid="SD1">Table S1</xref>).</p></sec><sec id="S4"><title>Maintenance of epigenetic response to RA is seen in neuroblastoma cell lines with <italic>ATRX</italic> IFF’s</title><p id="P13">We next assessed whether RA treatment induced expression of direct RA <italic>HOX</italic>-gene targets in two neuroblastoma cell lines with in-frame <italic>ATRX</italic> deletions: SK-N-MM and CHLA-90 [<xref ref-type="bibr" rid="R6">6</xref>]. In contrast to <italic>ATRX</italic> LoF cells, cell lines with the <italic>ATRX</italic> IFF were able to upregulate direct RA <italic>HOX</italic>-gene targets following treatment with RA (<xref ref-type="fig" rid="F2">Fig 2A</xref>). We then performed ATAC sequencing in the <italic>ATRX</italic> IFF cell lines to evaluate changes in chromatin accessibility following RA treatment (<xref ref-type="fig" rid="F2">Fig 2B</xref>). Large changes in chromatin accessibility in response to RA were seen in SK-N-MM (<xref ref-type="fig" rid="F2">Fig 2C</xref>, <xref ref-type="supplementary-material" rid="SD1">Table S2</xref>) and more limited changes in chromatin accessibility were seen in CHLA-90 (<xref ref-type="fig" rid="F2">Fig 2D</xref>, <xref ref-type="supplementary-material" rid="SD1">Table S2</xref>). Although comparisons could not be made with matched wild-type cells in these models, we noted that both cell lines showed highly significant increases in chromatin accessibility at the direct RA genes <italic>DHRS3, CYP26A</italic> and <italic>CYP26B</italic> in response to RA, alongside <italic>EXOC6B</italic> which sits adjacent to <italic>CYP26B</italic> on 2p13.2. Taken together, this identifies that <italic>ATRX</italic> IFF neuroblastoma can differentially open chromatin in response to RA at relevant gene sites.</p></sec><sec id="S5"><title><italic>ATRX</italic>-IFF neuroblastoma shows <italic>in-vitro</italic> sensitivity to RA</title><p id="P14">We next analysed RA sensitivity in available <italic>ATRX</italic> aberrant models. To our knowledge there are no currently available patient derived neuroblastoma cell lines with <italic>ATRX</italic> LoF. We identified a patient derived xenograft (PDX) neuroblastoma model with an <italic>ATRX</italic> p.Gly1748 mutation and treated this model with a clinically relevant dose of RA [<xref ref-type="bibr" rid="R18">18</xref>], 10 days after xenograft injection, and found no difference in tumour latency or growth in RA treated PDXs versus vehicle control (<xref ref-type="supplementary-material" rid="SD1">Fig S2A</xref>).</p><p id="P15">We next evaluated sensitivity to RA in <italic>ATRX</italic> IFF models. Others have shown that a non-canonical function of the ATRX-IFF in blocking neuronal differentiation results in sensitivity to EZH2 inhibition [<xref ref-type="bibr" rid="R6">6</xref>]. Therefore, we hypothesized that the combination of RA with EZH2 inhibition would be particularly effective for <italic>ATRX</italic> IFF neuroblastoma. Both ATRX IFF neuroblastoma cell lines showed sensitivity to RA as a single agent (<xref ref-type="fig" rid="F3">Fig 3A-D</xref>) and this was further augmented with the addition of either tazemetostat or the EZH2 degrader MS1943, at doses sufficient to reduce H3K27me3 levels (<xref ref-type="fig" rid="F3">Fig 3A-E</xref>).</p><p id="P16">Given the promising <italic>in-vitro</italic> results in <italic>ATRX</italic> IFF models, we evaluated <italic>in-vivo</italic> sensitivity to RA alone, and in combination with tazemetostat in the AMC772 <italic>ATRX</italic> IFF xenograft model. However here we saw no response to either agent alone, or in combination (<xref ref-type="fig" rid="F3">Fig 3F</xref>). Given the limitations in identifying <italic>in-vivo</italic> response to differentiation agents used in a minimal residual disease setting in a rapidly growing xenograft model, we assessed response to these agents in an organoid model developed from the AMC722 xenografts. Here, we identified <italic>in-vitro</italic> sensitivity to RA but did not see any sensitivity to tazemetostat at doses sufficient to reduce H3K27me3 levels (<xref ref-type="fig" rid="F3">Fig3 G-I</xref>). Taken together, our results identify that <italic>in-vitro</italic> sensitivity to RA, but not tazemetostat is consistent across multiple <italic>ATRX</italic> IFF models.</p></sec></sec><sec id="S6" sec-type="discussion"><title>Discussion</title><p id="P17">Despite increasing evidence that neuroblastoma consists of distinct molecular subgroups with different clinical phenotypes [<xref ref-type="bibr" rid="R2">2</xref>], all children with high-risk neuroblastoma are currently treated uniformly. RA has been used as maintenance therapy in the minimal residual disease setting for neuroblastoma for decades, with evidence of clinical benefit for some children [<xref ref-type="bibr" rid="R19">19</xref>]. However, it is extremely challenging to identify which patients are likely to benefit from RA given that it is used at the end of treatment in the minimal residual disease setting.</p><p id="P18">In pre-clinical studies, neuroblastoma with <italic>MYCN</italic> amplification has been shown to be generally sensitive to RA [<xref ref-type="bibr" rid="R20">20</xref>]. Here, we identify that <italic>ATRX</italic> IFF neuroblastoma is also generally sensitive to RA, and that ATRX IFF cell lines mount an appropriate epigenetic response to RA. In direct contrast, the epigenetic response to RA is impaired in <italic>ATRX</italic> LoF neuroblastoma. Our data suggests a high likelihood of RA resistance in <italic>ATRX</italic> LoF neuroblastoma, although the limitation of our study is that we were unable to directly evaluate sensitivity due to a lack of relevant models. Thus far, we have been unable to induce <italic>ATRX</italic> LoF via CRISPR-Cas9 in a RA sensitive cell line. We have also generated <italic>ATRX</italic> LoF clones from the NBL-S cell line [<xref ref-type="bibr" rid="R9">9</xref>]. However, NBL-S is highly RA resistant and does not upregulate direct target genes upon RA treatment (data not shown). This is likely to be because NBL-S carries an <italic>NF1</italic> mutation [<xref ref-type="bibr" rid="R21">21</xref>], which is has also been shown to result in RA resistance [<xref ref-type="bibr" rid="R22">22</xref>].</p><p id="P19">This highlights one of the significant challenges in the field, with a lack of appropriate models that reflect the heterogeneity of neuroblastoma seen in the clinic.</p><p id="P20">Here, our novel insight into the effects of <italic>ATRX</italic> LoF on neuroblastoma cell differentiation was triggered by an initial observation made in <italic>ATRX</italic> LoF iPSCs. Stem-cell models are increasingly being used to understand the underlying mechanisms of oncogenesis in neuroblastoma [<xref ref-type="bibr" rid="R23">23</xref>] and here, we show their potential to also give clinically relevant insight. Ongoing work in our laboratory and others to model the biological effects of specific <italic>ATRX</italic> alterations at later stages of neural crest differentiation will provide further insight, in addition to much needed pre-clinical models of neuroblastoma for future studies.</p><p id="P21">In conclusion, we demonstrate differences in chromatin response to RA in neuroblastoma according to type of <italic>ATRX</italic> alteration and propose that within the <italic>ATRX</italic> subgroup, there is likely to be significant heterogeneity in response to differentiation therapies depending on the precise type of alteration. This emphasises the need for improved patient stratification based on molecular features in the upfront treatment setting, alongside the need to develop novel approaches for certain subgroups of patients. Our work also highlights one of the major challenges in the field as we identify increasingly smaller molecular subgroups, each with differing underlying biology, within this already rare disease.</p></sec><sec id="S7" sec-type="methods"><title>Methods</title><table-wrap id="T1" orientation="portrait" position="anchor"><table frame="box" rules="groups"><thead><tr><th valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000;background: #e6e6e6">Reagent/Resource</th><th valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000;background: #e6e6e6">Reference or Source</th><th valign="top" align="left" style="border:solid 1px #000000;background:#E6E6E6">Identifier or Catalog Number</th></tr></thead><tbody><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000;background: #e6e6e6"><bold>Experimental Models</bold></td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000;background: #e6e6e6"/><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid #000000;background: #e6e6e6"/></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">SK0019 iPSC (wild-type and<break/><italic>ATRX</italic> LoF)</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">Provided by Stephen<break/>Scherer, Toronto [<xref ref-type="bibr" rid="R10">10</xref>]</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">N/A</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">p53(2) cell line</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">George et al, EBioMedicine, 2020 [<xref ref-type="bibr" rid="R14">14</xref>]</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">N/A</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">E6 cell line</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">George et al, EBioMedicine, 2020 [<xref ref-type="bibr" rid="R14">14</xref>]</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">N/A</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">CHLA-90</td><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">COG cell line repository, USA</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">N/A</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">SK-N-MM</td><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">Provided by Emily Bernstein, USA</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">N/A</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-bottom: 1px solid #000000;border-left: 1px solid">AMC772</td><td valign="top" align="left" style="border:solid 1px #000000">Provided by Jan Molenaar, Netherlands</td><td valign="top" align="left" style="border: 1px solid">N/A</td></tr><tr><td valign="top" align="left" style="border-left: 1px solid">IC-pPDX17</td><td valign="top" align="left" style="border-left: 1px solid #000000">Gudrun Schleiermacher, France [<xref ref-type="bibr" rid="R24">24</xref>]</td><td valign="top" align="left" style="border-left: 1px solid #000000;border-right: 1px solid">N/A</td></tr><tr><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000;background:#E6E6E6"><bold>Antibodies</bold></td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000;background: #e6e6e6"/><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid #000000;background: #e6e6e6"/></tr><tr><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">ATRX</td><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">Sigma</td><td valign="top" align="left" style="border:solid 1px #000000">HPA001906</td></tr><tr><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">GAPDH</td><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">Cell signaling</td><td valign="top" align="left" style="border:solid 1px #000000">2118</td></tr><tr><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">H3K27me3</td><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">Cell signaling</td><td valign="top" align="left" style="border:solid 1px #000000">C36B11</td></tr><tr><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">HRP conjugated anti-rabbit</td><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">Dako</td><td valign="top" align="left" style="border:solid 1px #000000">PO448</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000;background: #e6e6e6"><bold>Oligonucleotides and other</bold><break/><bold>sequence-based reagents</bold></td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000;background: #e6e6e6"/><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid #000000;background: #e6e6e6"/></tr><tr><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">HOXC4 primer</td><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">Dickson et al, 2009 [<xref ref-type="bibr" rid="R25">25</xref>]</td><td valign="top" align="left" style="border:solid 1px #000000">N/A</td></tr><tr><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">HOXC6 primer</td><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">Dickson et al, 2009 [<xref ref-type="bibr" rid="R25">25</xref>]</td><td valign="top" align="left" style="border:solid 1px #000000">N/A</td></tr><tr><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">HOXC9 primer</td><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">Dickson et al, 2009 [<xref ref-type="bibr" rid="R25">25</xref>]</td><td valign="top" align="left" style="border:solid 1px #000000">N/A</td></tr><tr><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">ATAC primers</td><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">Corces et al, 2017 [<xref ref-type="bibr" rid="R26">26</xref>]</td><td valign="top" align="left" style="border:solid 1px #000000">N/A</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000;background: #e6e6e6"><bold>Chemicals, Enzymes and</bold><break/><bold>other reagents</bold></td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000;background: #e6e6e6"/><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid #000000;background: #e6e6e6"/></tr><tr><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">NANOG taqman probe</td><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">ThermoFisher Scientific</td><td valign="top" align="left" style="border:solid 1px #000000">Hs02387400_g1</td></tr><tr><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">OCT4 taqman probe</td><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">ThermoFisher Scientific</td><td valign="top" align="left" style="border:solid 1px #000000">Hs04260367_gH</td></tr><tr><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">SOX2 taqman probe</td><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">ThermoFisher Scientific</td><td valign="top" align="left" style="border:solid 1px #000000">Hs04234836_s1</td></tr><tr><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">CDX2 taqman probe</td><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">ThermoFisher Scientific</td><td valign="top" align="left" style="border:solid 1px #000000">Hs01078080_m1</td></tr><tr><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">CYP26A taqman probe</td><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">ThermoFisher Scientific</td><td valign="top" align="left" style="border:solid 1px #000000">Hs00175627_m1</td></tr><tr><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">HOXA1 taqman probe</td><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">ThermoFisher Scientific</td><td valign="top" align="left" style="border:solid 1px #000000">Hs05047045_s1</td></tr><tr><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">HOXA4 taqman probe</td><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">ThermoFisher Scientific</td><td valign="top" align="left" style="border:solid 1px #000000">Hs01573270_m1</td></tr><tr><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">GAPDH taqman probe</td><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">ThermoFisher Scientific</td><td valign="top" align="left" style="border:solid 1px #000000">Hs02786624_g1</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">PowerUp™ SYBR™Green master mix for qPCR</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">ThermoFisher Scientific</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">A25743</td></tr><tr><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">Taqman™ Universal PCR master mix</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">ThermoFisher Scientific</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">4304437</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">Recombinant Human FGF-basic (146 aa) protein CF</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">R&amp;D systems</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">#233-FB/CF</td></tr><tr><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">CHIR99021</td><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">Tocris</td><td valign="top" align="left" style="border:solid 1px #000000">|4423</td></tr><tr><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">Geltrex basement membrane matrix</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">ThermoFischer</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">A1413201</td></tr><tr><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">Tagment DNA enzyme and buffer kit</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">Illumina</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">20034197</td></tr><tr><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">13-cis-retinoic acid</td><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">Sigma Aldrich</td><td valign="top" align="left" style="border:solid 1px #000000">R3255</td></tr><tr><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">Tazemetostat</td><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">Selleckchem</td><td valign="top" align="left" style="border:solid 1px #000000">S7128</td></tr><tr><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">MS1943</td><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">MedChemExpress</td><td valign="top" align="left" style="border:solid 1px #000000">HY-133129</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid #000000">Maxima First Strand cDNA synthesis kit for RT-qPCR</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">ThermoFisher Scientific</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">K1641</td></tr><tr><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">ACK lysis buffer</td><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">Thermofischer</td><td valign="top" align="left" style="border:solid 1px #000000">A1049201</td></tr><tr><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">GlutaMAX™</td><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">Thermofischer</td><td valign="top" align="left" style="border:solid 1px #000000">21885025</td></tr><tr><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">Ham’s F-12 Nutrient Mix</td><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">Thermofischer</td><td valign="top" align="left" style="border:solid 1px #000000">15344967</td></tr><tr><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">B-27 Supplement™ (50X)<break/>minus vitamin A</td><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">Thermofischer</td><td valign="top" align="left" style="border:solid 1px #000000">11530538</td></tr><tr><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">N-2 supplement</td><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">Thermofischer</td><td valign="top" align="left" style="border:solid 1px #000000">17502048</td></tr><tr><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">Recombinant Human EGF</td><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">PeproTech</td><td valign="top" align="left" style="border:solid 1px #000000">AF-100-15</td></tr><tr><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">recombinant Human FGF-basic</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">PeproTech</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">AF-100-18B</td></tr><tr><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">recombinant Human IGF-I</td><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">PeproTech</td><td valign="top" align="left" style="border:solid 1px #000000">100-11-100UG</td></tr><tr><td valign="top" align="left" style="border:solid 1px #000000">recombinant Human<break/>PDGF-AA and PDGF-BB</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-bottom: 1px solid #000000;border-left: 1px solid">PeproTech</td><td valign="top" align="left" style="border:solid 1px #000000">#100-13A<break/>#100-14B</td></tr></tbody></table></table-wrap><sec id="S8"><title>Cell culture and differentiation</title><p id="P22">Paired <italic>ATRX</italic> wild-type and LoF SK0019 iPSC’s were generated in the Scherer laboratory [<xref ref-type="bibr" rid="R10">10</xref>]. iPSCs were cultured on Geltrex™ reduced growth factor basement membrane and maintained in StemFlex™ media and differentiated into human axial progenitor cells using published protocols [<xref ref-type="bibr" rid="R11">11</xref>]. The neuroblastoma cell lines p53(2), E6, CHLA-90 and SK-N-MM were maintained in 10% fetal calf serum Dulbecco’s Modified Eagle Medium (DMEM). The AMC772 organoid cell line was generated from xenografts established in the adrenal gland of NSG mice. Tissue was minced and strained using 70 μm cell strainer. Cells were then washed with ACK lysis buffer for 5 minutes to remove red blood cells before inactivation using Low-glucose DMEM + 10% fetal calf serum. Cells were again washed in 10 mL DMEM low glucose GlutaMAX™. Cells were maintained in organoid media (DMEM low glucose GlutaMAX™ Filemented with: 25% Ham’s F-12 Nutrient Mix, B-27™ Supplement, N-2 Supplement, 100 U/mL penicillin and 100 μg/mL streptomycin, 40 ng/mL recombinant human EGF, 200 ng/mL recombinant human FGF-basic, 10 ng/mL recombinant human IGF-I, 10 ng/mL recombinant human PDGF-AA and PDGF-BB. 13-cis-retinoic acid, tazemetostat and MS1943 were all dissolved in dimethyl-sulfoxide (DMSO) to make 10 mM stock concentrations.</p></sec><sec id="S9"><title>Quantification of mRNA by RT-qPCR</title><p id="P23">RNA was isolated from cells using the Qiagen RNeasy kit and cDNA synthesized using the Maxima First Strand cDNA synthesis kit (ThermoFisher). Either commercially available Taqman probes or SYBR green probes with published sequences were used as indicated in the reagents table. qPCR reactions were performed as per manufacturer’s instructions using the QuantStudio3™ real time PCR machine. <italic>GAPDH</italic> was used as a housekeeping gene. Relative mRNA abundance of target genes was calculated by the 2(−ΔΔCq) method. Relative quantity compared with control was calculated and is displayed except for <italic>HOXA1</italic> and <italic>HOXA4</italic> expression in p53(2) and E6 cell lines where baseline levels were not detectable in untreated cells for comparison hence inverse log of delta CT is displayed. All RT-qPCR data is representative of at least 2 independent experiments, each performed in triplicate.</p></sec><sec id="S10"><title>ATAC sequencing</title><p id="P24">Neuroblastoma cell lines were treated with either vehicle control (DMSO) or 10 µM RA for 72 hours, before collection for ATAC sequencing. 25 000 cells were used per experiment and ATAC sequencing libraries were prepared using the OMNI-ATAC protocol [<xref ref-type="bibr" rid="R26">26</xref>], with modifications as previously published [<xref ref-type="bibr" rid="R27">27</xref>]. All ATAC-sequencing experiments were performed in biological triplicates. ATAC-sequencing was carried out at the Genomics facility at the Francis Crick Institute.</p></sec><sec id="S11"><title>ATAC sequencing data analysis</title><p id="P25">All ATAC sequencing data analyses were performed on the Crick HPC cluster using Nextflow v22.04.0 [<xref ref-type="bibr" rid="R28">28</xref>] and Singularity v3.6.4 [<xref ref-type="bibr" rid="R29">29</xref>]. The nf-core/atacseq pipeline (release 3.0) [<xref ref-type="bibr" rid="R28">28</xref>] was executed with the Crick profile for alignment, peak calling and quality control. The GRCh38, Ensembl release 95 genome reference was used. Consensus peaksets were imported into R [<xref ref-type="bibr" rid="R30">30</xref>] and analysed with DiffBind [<xref ref-type="bibr" rid="R31">31</xref>]. Counts were generated then normalised for library size and background. A generalised linear model incorporating Tissue, Treatment, and their interaction was specified. Normalised read counts for peaks were log<sub>2</sub>-transformed and principle component analysis (PCA) was performed on the transposed matrix using prcomp [<xref ref-type="bibr" rid="R30">30</xref>]. The percentage variance explained by PC1 and PC2 was calculated from the standard deviations. Scores were plotted with ggplot2 [<xref ref-type="bibr" rid="R32">32</xref>].</p><p id="P26">All peaks were annotated to the nearest genomic feature using ChIPpeakAnno [<xref ref-type="bibr" rid="R33">33</xref>]. Distance to TSS was calculated from peak midpoint. Peaks were annotated to nearest promoters using the Ensembl GRCh38.95 GTF. Promoter regions were defined as ±5 kb around the TSS. Overlaps between peak ranges and promoter windows were detected using IRanges::findOverlaps [<xref ref-type="bibr" rid="R34">34</xref>].</p><p id="P27">Differential binding results were retrieved, and a data frame was constructed with log<sub>2</sub> fold-change (x-axis), –log<sub>10</sub> FDR (y-axis), and a significance flag (FDR ≤ 0.05). Points exceeding |log<sub>2</sub> fold-change| &gt; 1 and –log<sub>10</sub> FDR &gt; 1 were labelled with gene symbols using ggrepel [<xref ref-type="bibr" rid="R35">35</xref>]. Volcano plots were drawn with ggplot2 [<xref ref-type="bibr" rid="R32">32</xref>].</p><p id="P28">For gene ontology (GO) enrichment, for each comparison, DiffBind output (Fold and FDR) was parsed into separate “up” and “down” gene lists. GO Biological Process enrichment was computed with clusterProfiler [<xref ref-type="bibr" rid="R36">36</xref>]. From the list of GO biological processes, redundant terms were eliminated using REVIGO (<ext-link ext-link-type="uri" xlink:href="http://revigo.irb.hr/">http://revigo.irb.hr/</ext-link>) [<xref ref-type="bibr" rid="R17">17</xref>]. A small list of GO terms was obtained and graphs were drawn with ggplot2.</p><p id="P29">Motif enrichment analysis was performed using position weight matrices (PWMs) for vertebrate transcription factors which were retrieved from JASPAR2020 [<xref ref-type="bibr" rid="R37">37</xref>]. Peaks were scanned for motif enrichment using monaLisa [<xref ref-type="bibr" rid="R38">38</xref>]: sequences were extracted from the GRCh38 genome fasta using Biostrings [<xref ref-type="bibr" rid="R39">39</xref>], binned by log2 fold-change into three bins (–10 to 0, 0–10), and motif enrichment calculated with calcBinnedMotifEnrR from the monaLisa package. Motifs with |log2 enrichment| &gt; fold-change threshold and –log10 padj &gt; threshold were retained. Similar motifs were clustered by Pearson similarity of PFMs and visualized as heatmaps with sequence-logos.</p></sec><sec id="S12"><title>Clonogenic assays</title><p id="P30">For adherent cell lines 1000-10000 cells were plated in 2 ml medium, in triplicate in 6-well plates. After 24 hours medium was exchanged and drugs or DMSO added and cells cultured for 1–3 weeks, with fresh drug containing media being replaced twice weekly. 10 µM RA was used for all cell lines, except for CHLA-90 which was treated with 100 nM RA for the clonogenic assay, CHLA-90 and SK-N-MM cell lines were treated with 5 µM of either tazemetostat or MS1943. Adherent cells were stained by 0.01% crystal violet in distilled water for 30 minutes at room temperature, then washed before drying of the plates overnight. Plates were visualized using the gelcount machine (Oxford Optronix). Confluency was calculated using imageJ processing software.</p><p id="P31">Cell Titer-Glo 3D was used to assess treatment response in the AMC772 organoid model. A total of 20000 cells were plated in triplicate in 100 μL of organoid media in an opaque 96-well plate and incubated for 4 days in humidified incubator at 37°C with 5% CO<sub>2</sub> to allow spheroid formation. Following spheroid formation, the media was replaced with 100 μL of fresh media containing either DMSO, Tazmetostat and/or RA, then incubated for an additional seven days, with imaging performed on the Opera Phenix™ on days 1, 3, 5, and 7 post-treatments. On day 7, 100 μL CellTiter-Glo® 3D Reagent (Promega Cat#G9681) was added to each well mixed on an orbital shaker for 10 minutes then allowed to stabilize for 30 minutes before fluorescence was measured at 560 nm using a spectrometer.</p></sec><sec id="S13"><title>Western blot</title><p id="P32">SK-N-MM and CHLA-90 were treated with tazemetostat and MS-1943 at a concentration of 2.5 µM for 72 hours then proteins were isolated by Pierce IP Lysis buffer containing phosphatase inhibitor cocktail.</p><p id="P33">For the AMC772 organoids, 200000 cells were seeded in triplicate into 6-well plates with 2.5 mL of organoid media and incubated for 4 days in humidified incubator at 37°C with 5% CO<sub>2</sub> to allow spheroid formation. Following spheroid formation, the media was replaced with 2.5 mL of fresh media containing either DMSO, tazmetostat and/or RA. Cells were then incubated for an additional seven days before cells lysis in 1X RIPA lysis buffer supplemented with a protease inhibitor and phosphatase inhibitor cocktail.</p><p id="P34">Protein concentrations were measured by BCA protein assay. Membranes were incubated overnight with primary antibodies, washed with TBS-T and then incubated 1 hour at room temperature with the secondary antibody listed in the reagents table. Membranes were incubated with Clarity™ Western ECL Substrate before imaging using the ChemiDoc™ Imaging System (Bio-Rad).</p></sec><sec id="S14"><title><italic>In-vivo</italic> experiments</title><p id="P35">AMC772 xenografts were established subcutaneously in NOD scid gamma (NSG) mice as published previously [<xref ref-type="bibr" rid="R40">40</xref>]. Tumour development was monitored by palpation by an experienced technician and animals randomly allocated to treatment arms once a tumour was palpable. The clinically relevant dose of 53 mg/kg 13-<italic>cis</italic>-retinoic acid was used [<xref ref-type="bibr" rid="R18">18</xref>], administered via oral gavage once daily, Monday to Friday, dissolved in a total volume of 200 µL corn oil. Tazemetostat was administered at a dose of 10 mg/kg intraperitoneally once daily, Monday–Friday, in 50 µL total volume of 5% DMSO (+4.5% PEG300, 5% tween and ddH20). Mice were housed in autoclaved, aseptic cages in specific pathogen-free rooms in The Institute of Cancer Research (ICR) animal facility and allowed access to sterile food and water ad libitum. Experiments were approved by The ICR Animal Welfare and Ethical Review Body and performed in accordance with the UK Home Office Animals (Scientific Procedures) Act 1986, the UK National Cancer Research Institute guidelines for the welfare of animals in cancer research and the ARRIVE (animal research: reporting <italic>in-vivo</italic> experiments) guidelines.</p><p id="P36">The IC-pPDX17 was established from a NB tumour biopsy following informed consent from the parents, as published previously [<xref ref-type="bibr" rid="R24">24</xref>, <xref ref-type="bibr" rid="R41">41</xref>].Swiss Nude mice were engrafted with tumours in their interscapular fat pad on day 0 (D0). Treatment with 13cRA or vehicle injection began on day 10 (D10) after tumour engraftment. The mice then received daily intraperitoneal injections of either RA or vehicle control 5 days per week for three weeks. Mouse weight and tumour size were monitored three times per weekly. Mice were euthanized when tumours reached a predetermined ethical size limit of approximately 1,500-2,000 mm<sup>3</sup>. All procedures were approved by the Institutional Review Board of the Institut Curie. All animal experiments complied with current European/French legislation (articles R.214-87 to R.214-126 of the Decree n°2013-118 of February 1st) and were carried out in accredited animal facilities of the Institut Curie.</p></sec></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplementary Materials</label><media xlink:href="EMS207359-supplement-Supplementary_Materials.pdf" mimetype="application" mime-subtype="pdf" id="d11aAcEbB" position="anchor"/></supplementary-material></sec></body><back><ack id="S15"><title>Acknowledgements</title><p>We would like to thank Stephen Scherer for sharing the <italic>ATRX</italic> WT and LoF IPSC’s generated in his laboratory and Tom Frith for his help and support with IPSC neural crest differentiation protocols.</p><p>FL and SLG are supported by a Cancer Research UK Clinician Scientist Fellowship. MS, LC and SLG are supported by ICR HEFCE funding. LD is supported by a CCLG Little Princess Trust Project Grant. VT is supported by funding from the ArcoBaleno Trust/Siobhan’s Superstar legacy. KB is supported by the nMGN Cancer Cluster, MRC</p><p>KG and BC are supported by Chesler CR UK Prog Award A28278. KC is also supported by the Brain Tumour Charity (GN-000690).</p><p>In France, this work was supported by the Annenberg Foundation, the Association Hubert Gouin Enfance et Cancer, Imagine for Margo, the Fondation ARC pour la Recherche contre le Cancer (ARC), and Fights Kids Cancer. Establishment of PDX models was performed under the MAPPYACTS protocol (clinicaltrial.gov: NCT02613962). Molecular characterization of the PDX models was supported within the framework of the IMI2 ITCC P4 program funded by IMI2 grant agreement no. 116064 ITCC-P4.</p></ack><fn-group><fn fn-type="conflict" id="FN1"><p id="P37"><bold>Disclosure and Competing Interest Statement</bold></p><p id="P38">The authors have no conflicts of interest to declare</p></fn></fn-group><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ackermann</surname><given-names>S</given-names></name><etal/></person-group><article-title>A mechanistic classification of clinical phenotypes in neuroblastoma</article-title><source>Science</source><year>2018</year><volume>362</volume><issue>6419</issue><fpage>1165</fpage><lpage>1170</lpage><pub-id pub-id-type="doi">10.1126/science.aat6768</pub-id><pub-id pub-id-type="pmcid">PMC7875194</pub-id><pub-id pub-id-type="pmid">30523111</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeineldin</surname><given-names>M</given-names></name><etal/></person-group><article-title>MYCN amplification and ATRX mutations are incompatible in neuroblastoma</article-title><source>Nat Commun</source><year>2020</year><volume>11</volume><issue>1</issue><fpage>913</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-14682-6</pub-id><pub-id pub-id-type="pmcid">PMC7021759</pub-id><pub-id pub-id-type="pmid">32060267</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>NK</given-names></name><etal/></person-group><article-title>Association of age at diagnosis and genetic mutations in patients with neuroblastoma</article-title><source>JAMA</source><year>2012</year><volume>307</volume><issue>10</issue><fpage>1062</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1001/jama.2012.228</pub-id><pub-id pub-id-type="pmcid">PMC3527076</pub-id><pub-id pub-id-type="pmid">22416102</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aguilera</surname><given-names>P</given-names></name><name><surname>Lopez-Contreras</surname><given-names>AJ</given-names></name></person-group><article-title>ATRX, a guardian of chromatin</article-title><source>Trends Genet</source><year>2023</year><volume>39</volume><issue>6</issue><fpage>505</fpage><lpage>519</lpage><pub-id pub-id-type="pmid">36894374</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Gerven</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Mutational spectrum of ATRX aberrations in neuroblastoma and associated patient and tumor characteristics</article-title><source>Cancer Sci</source><year>2022</year><volume>113</volume><issue>6</issue><fpage>2167</fpage><lpage>2178</lpage><pub-id pub-id-type="doi">10.1111/cas.15363</pub-id><pub-id pub-id-type="pmcid">PMC9207354</pub-id><pub-id pub-id-type="pmid">35384159</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qadeer</surname><given-names>ZA</given-names></name><etal/></person-group><article-title>ATRX In-Frame Fusion Neuroblastoma Is Sensitive to EZH2 Inhibition via Modulation of Neuronal Gene Signatures</article-title><source>Cancer Cell</source><year>2019</year><volume>36</volume><issue>5</issue><fpage>512</fpage><lpage>527</lpage><elocation-id>e9</elocation-id><pub-id pub-id-type="doi">10.1016/j.ccell.2019.09.002</pub-id><pub-id pub-id-type="pmcid">PMC6851493</pub-id><pub-id pub-id-type="pmid">31631027</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Gerven</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Two opposing gene expression patterns within ATRX aberrant neuroblastoma</article-title><source>PLOS ONE</source><year>2023</year><volume>18</volume><issue>8</issue><elocation-id>e0289084</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0289084</pub-id><pub-id pub-id-type="pmcid">PMC10403137</pub-id><pub-id pub-id-type="pmid">37540673</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pugh</surname><given-names>TJ</given-names></name><etal/></person-group><article-title>The genetic landscape of high-risk neuroblastoma</article-title><source>Nat Genet</source><year>2013</year><volume>45</volume><issue>3</issue><fpage>279</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1038/ng.2529</pub-id><pub-id pub-id-type="pmcid">PMC3682833</pub-id><pub-id pub-id-type="pmid">23334666</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lorenzi</surname><given-names>F</given-names></name><etal/></person-group><article-title>ATRX mutations mediate an immunogenic phenotype and macrophage infiltration in neuroblastoma</article-title><source>Cancer Lett</source><year>2025</year><elocation-id>217495</elocation-id><pub-id pub-id-type="doi">10.1016/j.canlet.2025.217495</pub-id><pub-id pub-id-type="pmcid">PMC12057689</pub-id><pub-id pub-id-type="pmid">39892705</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deneault</surname><given-names>E</given-names></name><etal/></person-group><article-title>Complete Disruption of Autism-Susceptibility Genes by Gene Editing Predominantly Reduces Functional Connectivity of Isogenic Human Neurons</article-title><source>Stem Cell Reports</source><year>2018</year><volume>11</volume><issue>5</issue><fpage>1211</fpage><lpage>1225</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2018.10.003</pub-id><pub-id pub-id-type="pmcid">PMC6235011</pub-id><pub-id pub-id-type="pmid">30392976</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frith</surname><given-names>TJR</given-names></name><name><surname>Tsakiridis</surname><given-names>A</given-names></name></person-group><article-title>Efficient Generation of Trunk Neural Crest and Sympathetic Neurons from Human Pluripotent Stem Cells Via a Neuromesodermal Axial Progenitor Intermediate</article-title><source>Curr Protoc Stem Cell Biol</source><year>2019</year><volume>49</volume><issue>1</issue><fpage>e81</fpage><pub-id pub-id-type="doi">10.1002/cpsc.81</pub-id><pub-id pub-id-type="pmcid">PMC6520238</pub-id><pub-id pub-id-type="pmid">30688409</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>T</given-names></name><etal/></person-group><article-title>Cdx and Hox genes differentially regulate posterior axial growth in mammalian embryos</article-title><source>Dev Cell</source><year>2009</year><volume>17</volume><issue>4</issue><fpage>516</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">19853565</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lengerke</surname><given-names>C</given-names></name><etal/></person-group><article-title>The cdx-hox pathway in hematopoietic stem cell formation from embryonic stem cells</article-title><source>Ann N Y Acad Sci</source><year>2007</year><volume>1106</volume><fpage>197</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">17303828</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>SL</given-names></name><etal/></person-group><article-title>Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma</article-title><source>EBioMedicine</source><year>2020</year><volume>59</volume><elocation-id>102971</elocation-id><pub-id pub-id-type="doi">10.1016/j.ebiom.2020.102971</pub-id><pub-id pub-id-type="pmcid">PMC7452577</pub-id><pub-id pub-id-type="pmid">32846370</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balmer</surname><given-names>JE</given-names></name><name><surname>Blomhoff</surname><given-names>R</given-names></name></person-group><article-title>Gene expression regulation by retinoic acid</article-title><source>J Lipid Res</source><year>2002</year><volume>43</volume><issue>11</issue><fpage>1773</fpage><lpage>808</lpage><pub-id pub-id-type="pmid">12401878</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Super-enhancer associated core regulatory circuits mediate susceptibility to retinoic acid in neuroblastoma cells</article-title><source>Front Cell Dev Biol</source><year>2022</year><volume>10</volume><elocation-id>943924</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2022.943924</pub-id><pub-id pub-id-type="pmcid">PMC9485839</pub-id><pub-id pub-id-type="pmid">36147741</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Supek</surname><given-names>F</given-names></name><etal/></person-group><article-title>REVIGO summarizes and visualizes long lists of gene ontology terms</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><issue>7</issue><elocation-id>e21800</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0021800</pub-id><pub-id pub-id-type="pmcid">PMC3138752</pub-id><pub-id pub-id-type="pmid">21789182</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nolting</surname><given-names>S</given-names></name><etal/></person-group><article-title>Combination of 13-Cis retinoic acid and lovastatin: marked antitumor potential in vivo in a pheochromocytoma allograft model in female athymic nude mice</article-title><source>Endocrinology</source><year>2014</year><volume>155</volume><issue>7</issue><fpage>2377</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1210/en.2014-1027</pub-id><pub-id pub-id-type="pmcid">PMC4060189</pub-id><pub-id pub-id-type="pmid">24762141</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matthay</surname><given-names>KK</given-names></name><etal/></person-group><article-title>Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group</article-title><source>N Engl J Med</source><year>1999</year><volume>341</volume><issue>16</issue><fpage>1165</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">10519894</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zimmerman</surname><given-names>MW</given-names></name><etal/></person-group><article-title>Retinoic acid rewires the adrenergic core regulatory circuitry of childhood neuroblastoma</article-title><source>Sci Adv</source><year>2021</year><volume>7</volume><issue>43</issue><elocation-id>eabe0834</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.abe0834</pub-id><pub-id pub-id-type="pmcid">PMC8528416</pub-id><pub-id pub-id-type="pmid">34669465</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Izquierdo</surname><given-names>E</given-names></name><etal/></person-group><article-title>Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumours</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><issue>67</issue><fpage>112036</fpage><lpage>112050</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.23000</pub-id><pub-id pub-id-type="pmcid">PMC5762377</pub-id><pub-id pub-id-type="pmid">29340109</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holzel</surname><given-names>M</given-names></name><etal/></person-group><article-title>NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome</article-title><source>Cell</source><year>2010</year><volume>142</volume><issue>2</issue><fpage>218</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.06.004</pub-id><pub-id pub-id-type="pmcid">PMC2913027</pub-id><pub-id pub-id-type="pmid">20655465</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saldana-Guerrero</surname><given-names>IM</given-names></name><etal/></person-group><article-title>A human neural crest model reveals the developmental impact of neuroblastoma-associated chromosomal aberrations</article-title><source>Nat Commun</source><year>2024</year><volume>15</volume><issue>1</issue><elocation-id>3745</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-024-47945-7</pub-id><pub-id pub-id-type="pmcid">PMC11068915</pub-id><pub-id pub-id-type="pmid">38702304</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boeva</surname><given-names>V</given-names></name><etal/></person-group><article-title>Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries</article-title><source>Nat Genet</source><year>2017</year><volume>49</volume><issue>9</issue><fpage>1408</fpage><lpage>1413</lpage><pub-id pub-id-type="pmid">28740262</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dickson</surname><given-names>GJ</given-names></name><name><surname>Lappin</surname><given-names>TR</given-names></name><name><surname>Thompson</surname><given-names>A</given-names></name></person-group><article-title>Complete array of HOX gene expression by RQ-PCR</article-title><source>Methods Mol Biol</source><year>2009</year><volume>538</volume><fpage>369</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">19277582</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corces</surname><given-names>MR</given-names></name><etal/></person-group><article-title>An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues</article-title><source>Nat Methods</source><year>2017</year><volume>14</volume><issue>10</issue><fpage>959</fpage><lpage>962</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4396</pub-id><pub-id pub-id-type="pmcid">PMC5623106</pub-id><pub-id pub-id-type="pmid">28846090</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lattke</surname><given-names>M</given-names></name><etal/></person-group><article-title>Extensive transcriptional and chromatin changes underlie astrocyte maturation in vivo and in culture</article-title><source>Nat Commun</source><year>2021</year><volume>12</volume><issue>1</issue><elocation-id>4335</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-24624-5</pub-id><pub-id pub-id-type="pmcid">PMC8282848</pub-id><pub-id pub-id-type="pmid">34267208</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ewels</surname><given-names>PA</given-names></name><etal/></person-group><article-title>The nf-core framework for community-curated bioinformatics pipelines</article-title><source>Nat Biotechnol</source><year>2020</year><volume>38</volume><issue>3</issue><fpage>276</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">32055031</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurtzer</surname><given-names>GM</given-names></name><name><surname>Sochat</surname><given-names>V</given-names></name><name><surname>Bauer</surname><given-names>MW</given-names></name></person-group><article-title>Singularity: Scientific containers for mobility of compute</article-title><source>PLoS One</source><year>2017</year><volume>12</volume><issue>5</issue><elocation-id>e0177459</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0177459</pub-id><pub-id pub-id-type="pmcid">PMC5426675</pub-id><pub-id pub-id-type="pmid">28494014</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="book"><source>R: A language and environment for statistical computing</source><publisher-name>R Foundation for Statistical Computing</publisher-name><year>2023</year><comment><ext-link ext-link-type="uri" xlink:href="https://www.R-project.org/">https://www.R-project.org/</ext-link></comment></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stark</surname><given-names>AB</given-names></name><name><surname>D</surname><given-names>G</given-names></name></person-group><article-title>DiffBind: differential binding analysis of ChIP-seq peak data</article-title><source>Bioinformatics</source><year>2011</year><volume>27</volume></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wickham</surname><given-names>H</given-names></name></person-group><source>ggplot2: Elegant Graphics for Data Analysis</source><publisher-name>Springer-Verlag</publisher-name><publisher-loc>New York</publisher-loc><year>2016</year></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>LJ</given-names></name><etal/></person-group><article-title>ChIPpeakAnno: a Bioconductor package to annotate ChIP-seq and ChIP-chip data</article-title><source>BMC Bioinformatics</source><year>2010</year><volume>11</volume><fpage>237</fpage><pub-id pub-id-type="doi">10.1186/1471-2105-11-237</pub-id><pub-id pub-id-type="pmcid">PMC3098059</pub-id><pub-id pub-id-type="pmid">20459804</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawrence</surname><given-names>M</given-names></name><etal/></person-group><article-title>Software for computing and annotating genomic ranges</article-title><source>PLoS Comput Biol</source><year>2013</year><volume>9</volume><issue>8</issue><elocation-id>e1003118</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1003118</pub-id><pub-id pub-id-type="pmcid">PMC3738458</pub-id><pub-id pub-id-type="pmid">23950696</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Slowikowsi</surname><given-names>K</given-names></name></person-group><source>ggrepel: Automatically position non-overlapping text labels with ‘ggplot2’. R package version 0.9.1</source><year>2021</year></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>G</given-names></name><etal/></person-group><article-title>clusterProfiler: an R package for comparing biological themes among gene clusters</article-title><source>OMICS</source><year>2012</year><volume>16</volume><issue>5</issue><fpage>284</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1089/omi.2011.0118</pub-id><pub-id pub-id-type="pmcid">PMC3339379</pub-id><pub-id pub-id-type="pmid">22455463</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fornes</surname><given-names>O</given-names></name><etal/></person-group><article-title>JASPAR 2020: update of the open-access database of transcription factor binding profiles</article-title><source>Nucleic Acids Res</source><year>2020</year><volume>48</volume><issue>D1</issue><fpage>D87</fpage><lpage>D92</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz1001</pub-id><pub-id pub-id-type="pmcid">PMC7145627</pub-id><pub-id pub-id-type="pmid">31701148</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krebs</surname><given-names>ARBM</given-names></name><name><surname>Starlinger</surname><given-names>J</given-names></name><name><surname>Lähnemann</surname><given-names>D</given-names></name></person-group><article-title>monaLisa: a fast and flexible tool for motif analysis in large-scale sequencing data</article-title><source>Bioinformatics</source><year>2021</year><volume>37</volume></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pages</surname><given-names>HA</given-names></name><name><surname>Gentleman</surname><given-names>R</given-names></name><name><surname>DebRoy</surname><given-names>S</given-names></name></person-group><source>Biostrings: String objects representing biological sequences, and matching algorithms. R package version 2.68.1</source><year>2023</year><comment>R package version 2681</comment></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>SL</given-names></name><etal/></person-group><article-title>A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations</article-title><source>Eur J Cancer</source><year>2019</year><volume>121</volume><fpage>224</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2019.07.027</pub-id><pub-id pub-id-type="pmcid">PMC6839402</pub-id><pub-id pub-id-type="pmid">31543384</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marques Da Costa</surname><given-names>ME</given-names></name><etal/></person-group><article-title>A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors</article-title><source>Commun Biol</source><year>2023</year><volume>6</volume><issue>1</issue><fpage>949</fpage><pub-id pub-id-type="doi">10.1038/s42003-023-05320-0</pub-id><pub-id pub-id-type="pmcid">PMC10507044</pub-id><pub-id pub-id-type="pmid">37723198</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><title><italic>ATRX</italic> LoF neuroblastoma cells have an impaired chromatin response to RA compared to their wild-type counterparts.</title><p><bold>(A)</bold> Time course experiment showing expression of <italic>CYP26A</italic>, normalized to <italic>GAPDH</italic> following exposure of p53(2) (<italic>ATRX</italic> wildtype) and E6 (<italic>ATRX</italic> LoF) cells to retinoic acid (RA). <bold>(B)</bold> <italic>HOXA1</italic> and <italic>HOXA4</italic> expression by RT-qPCR following 72 hours treatment with RA, compared to vehicle control. Inverse log delta CT is indicated. Where no expression was seen, this is indicated as 0. For all RT-qPCR experiments: <italic>t</italic> test, *<italic>P</italic> &lt; 0.05. <bold>(C)</bold> Clonogenic assay results for p53(2) and E6 cell lines following treatment with 10µM RA versus control (<italic>t</italic> test, ***<italic>P</italic> &lt; 0.001). <bold>(D-E)</bold> Volcano plots showing differentially accessible regions in E6 versus p53(2) cell lines following <bold>(D)</bold> vehicle control treatment conditions and <bold>(E)</bold> RA treatment. <bold>(F)</bold> Venn diagrams comparing differentially accessible transcription factor binding motifs following RA treatment in p53(2) and E6 cell lines. <bold>(G-J)</bold> Gene ontology analysis, comparing differential accessibility at gene promoters between E6 and p53(2) lines in <bold>(G)</bold> vehicle control treated conditions and <bold>(H)</bold> following treatment with RA. Displayed terms have been selected using REVIGO which eliminates redundant GO terms. <bold>(I-J)</bold> List of pathways grouped under the term “regionalization” and “embryonic skeletal system development” by Revigo for <bold>(I)</bold> vehicle control and <bold>(J)</bold> RA treated samples, respectively.</p></caption><graphic xlink:href="EMS207359-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>ATRX IFF neuroblastoma cell lines show increased chromatin accessibility and upregulation of direct RA target genes in response to RA.</title><p><bold>(A)</bold> <italic>HOXA1</italic> and <italic>HOXA4</italic> expression by RT-qPCR following RA treatment of SK-N-MM and CHLA-90 cell lines. *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001 <bold>(B)</bold> PCA plot showing ATAC sequencing data for 3 independent biological replicates following vehicle or RA treatment of the SK-N-MM and CHLA-90 cell lines. <bold>(C-D)</bold> Volcano plots showing differential accessibility in <bold>(C)</bold> SK-N-MM and <bold>(D)</bold> CHLA90 cell lines following RA treatment.</p></caption><graphic xlink:href="EMS207359-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><title>ATRX IFF neuroblastoma models show <italic>in vitro</italic> sensitivity to RA.</title><p>Results of clonogenic assay in response to RA alone and in combination with the EZH2 inhibitors tazemetostat (taz) and MS1943 in <bold>(A-B)</bold> SK-N-MM and <bold>(C-D)</bold> CHLA-90. <bold>(E)</bold> Western blot for H3K27me3 levels following treatment with different EZH2i as indicated at 2.5 µM concentration. GAPDH was used as loading control. <bold>(F)</bold> Tumor volume of the AMC772 <italic>in vivo</italic> xenograft models in response to RA +/-tazemetostat. <bold>(G-I)</bold> <italic>In vitro</italic> response to RA +/- tazemetostat in the AMC772 patient derived organoid (PDO) model. <bold>(G)</bold> Cells were treated with 10 µM RA alone and in combination with 10 µM tazemetostat and cell viability measured via Cell Titer Glo luminescence assay. <bold>(H)</bold> Representative images showing cell confluency following seven days exposure to RA alone and/or in combination with 10 µM tazemetostat. <bold>(I)</bold> H3K27me3 levels following treatment with different doses of tazemetostat that were evaluated <italic>in vitro</italic>. GAPDH was used as loading control.</p></caption><graphic xlink:href="EMS207359-f003"/></fig></floats-group></article>